|
OESTROGENS INCREASE LEVEL OF CORTICOSTEROID-BINDING GLOBULIN THERE BY INCREASING BOUND FRACTION, BUT ITS METABOLISM IS ALSO DECREASED,SO STEROID DOSE SHOULD BE REDUCED BUT INCREASED DOSE MAY BE REQUIRED WHEN OESTROGEN IS TERMINATED
|
CORTICOSTEROIDS TEND TO PRODUCE HYPERGLYCEMIA LEADING TO LOSS OF DIABETES CONTROL
|
CONCURRENT USE MAY CAUSE / POTENTIATE HYPOKALEMIA WHICH COULD PREDISPOSE THE PATIENT TO CARDIAC DYSFUNCTION
|
INCREASED RISK OF HYPOKALEMIA
|
CORTICOSTEROIDS MAY INCREASE EXCRETION OF THE DRUG
|
CONCURRENT ADMINISTRATION MAY LEAD TO INCREASED G.I. SIDE EFFECTS
|
HYPOKALEMIC EFFECT OF CORTICOSTEROIDS IS POTENTIATED
|
NSAIDS CONCURRENT ADMINISTRATION MAY INCREASE THE INCIDENCE OF G.I. SIDE EFFECTS
|
CONCURRENT ADMINISTRATION MAY LEAD TO INCREASED G.I. SIDE EFFECTS
|
CONCURRENT USE MAY CAUSE / POTENTIATE HYPOKALEMIA WHICH COULD PREDISPOSE THE PATIENT TO CARDIAC DYSFUNCTION
|
INCREASED RISK OF HYPOKALEMIA
|
CONCURRENT USE MAY CAUSE / POTENTIATE HYPOKALEMIA WHICH COULD PREDISPOSE THE PATIENT TO CARDIAC DYSFUNCTION
|
CO-ADMINISTRATION WITH CORTICOSTEROIDS MAY INCREASE THE RISK OF HYPOKALEMIA
|
CORTICOSTEROIDS TEND TO PRODUCE HYPERGLYCEMIA LEADING TO LOSS OF DIABETES CONTROL
|
CORTICOSTEROIDS TEND TO PRODUCE HYPERGLYCEMIA LEADING TO LOSS OF DIABETES CONTROL
|
CORTICOSTEROIDS TEND TO PRODUCE HYPERGLYCEMIA LEADING TO LOSS OF DIABETES CONTROL
|
CORTICOSTEROIDS TEND TO PRODUCE HYPERGLYCEMIA LEADING TO LOSS OF DIABETES CONTROL
|
CORTICOSTEROIDS MAY INCREASE EXCRETION OF THE DRUG
|
CONCURRENT ADMINISTRATION MAY LEAD TO INCREASED G.I. SIDE EFFECTS
|
CORTICOSTEROIDS CAN DECREASE SERUM CONCENTRATION OF ANTIMUSCARINIC AGENTS
|
CORTICOSTEROIDS MAY INTERFERE WITH THE DEVELOPMENT OF IMMUNE REACTION
|
CORTICOSTEROIDS MAY INTERFERE WITH THE DEVELOPMENT OF IMMUNE REACTION
|
CORTICOSTEROIDS MAY INTERFERE WITH THE DEVELOPMENT OF IMMUNE REACTION
|
CORTICOSTEROIDS MAY INTERFERE WITH THE DEVELOPMENT OF IMMUNE REACTION
|
CORTICOSTEROIDS MAY INTERFERE WITH THE DEVELOPMENT OF IMMUNE REACTION
|
CORTICOSTEROIDS TEND TO PRODUCE HYPERGLYCEMIA LEADING TO LOSS OF DIABETES CONTROL
|
CORTICOSTEROIDS TEND TO PRODUCE HYPERGLYCEMIA LEADING TO LOSS OF DIABETES CONTROL
|
CORTICOSTEROIDS TEND TO PRODUCE HYPERGLYCEMIA LEADING TO LOSS OF DIABETES CONTROL
|
CORTICOSTEROIDS TEND TO PRODUCE HYPERGLYCEMIA LEADING TO LOSS OF DIABETES CONTROL
|
CORTICOSTEROIDS TEND TO PRODUCE HYPERGLYCEMIA LEADING TO LOSS OF DIABETES CONTROL
|
CORTICOSTEROIDS TEND TO PRODUCE HYPERGLYCEMIA LEADING TO LOSS OF DIABETES CONTROL
|
CONCURRENT USE MAY CAUSE / POTENTIATE HYPOKALEMIA WHICH COULD PREDISPOSE THE PATIENT TO CARDIAC DYSFUNCTION
|
CONCURRENT USE MAY CAUSE / POTENTIATE HYPOKALEMIA WHICH COULD PREDISPOSE THE PATIENT TO CARDIAC DYSFUNCTION
|
CONCURRENT ADMINISTRATION MAY LEAD TO INCREASED G.I. SIDE EFFECTS
|
CORTICOSTEROIDS SHOULD BE USED CAUTIOUSLY SINCE THEY MAY ACCELERATE THE SPREAD OF VIRAL INFECTION
|
OESTROGENS INCREASE LEVEL OF CORTICOSTEROID-BINDING GLOBULIN THERE BY INCREASING BOUND FRACTION, BUT ITS METABOLISM IS ALSO DECREASED,SO STEROID DOSE SHOULD BE REDUCED BUT INCREASED DOSE MAY BE REQUIRED WHEN OESTROGEN IS TERMINATED
|
OESTROGENS CAUSE INCREASED LEVELS OF CORTICOSTEROID-BINDING GLOBULIN THEREBY INCREASING BOUND FRACTION, BUT ITS METABOLISM IS ALSO DECREASED.SO WITH OESTROGEN THERAPY STEROID DOSE SHOULD BE REDUCED & INCREASED WHEN OESTROGEN IS TERMINATED
|
CORTICOSTEROIDS MAY INCREASE EXCRETION OF THE DRUG
|
CONCURRENT ADMINISTRATION MAY LEAD TO INCREASED G.I. SIDE EFFECTS
|
NSAIDS CONCURRENT ADMINISTRATION MAY INCREASE THE INCIDENCE OF G.I. SIDE EFFECTS
|
CONCURRENT ADMINISTRATION MAY LEAD TO INCREASED G.I. SIDE EFFECTS
|
NSAIDS CONCURRENT ADMINISTRATION MAY INCREASE THE INCIDENCE OF G.I. SIDE EFFECTS
|
OESTROGENS CAUSE INCREASED LEVELS OF CORTICOSTEROID-BINDING GLOBULIN THEREBY INCREASING BOUND FRACTION, BUT ITS METABOLISM IS ALSO DECREASED.SO WITH OESTROGEN THERAPY STEROID DOSE SHOULD BE REDUCED & INCREASED WHEN OESTROGEN IS TERMINATED
|
CORTICOSTEROIDS CAN CAUSE HYPOKALEMIA OR HYPOMAGNESEMIA AND POTASSIUM OR MAGNESIUM DEPLETION CAN SENSITIZE THE MYOCARDIUM TO DIGOXIN RESULTING IN DIGTALIS TOXICITY
|
CORTICOSTEROIDS MAY INTERFERE WITH THE DEVELOPMENT OF IMMUNE REACTION
|
CORTICOSTEROIDS MAY INTERFERE WITH THE DEVELOPMENT OF IMMUNE REACTION
|
HYPOKALEMIC EFFECT OF CORTICOSTEROIDS IS POTENTIATED
|
CORTICOSTEROIDS MAY INTERFERE WITH THE DEVELOPMENT OF IMMUNE REACTION
|
CO-ADMINISTRATION MAY POTENTIATE HYPERTENSIVE EFFECT OF THE DRUG
|
CO-ADMINISTRATION MAY POTENTIATE HYPERTENSIVE EFFECT OF THE DRUG
|
HYPOKALEMIC EFFECT OF CORTICOSTEROIDS IS POTENTIATED
|
OESTROGENS CAUSE INCREASED LEVELS OF CORTICOSTEROID-BINDING GLOBULIN THEREBY INCREASING BOUND FRACTION, BUT ITS METABOLISM IS ALSO DECREASED.SO WITH OESTROGEN THERAPY STEROID DOSE SHOULD BE REDUCED & INCREASED WHEN OESTROGEN IS TERMINATED
|
OESTROGENS CAUSE INCREASED LEVELS OF CORTICOSTEROID-BINDING GLOBULIN THEREBY INCREASING BOUND FRACTION, BUT ITS METABOLISM IS ALSO DECREASED.SO WITH OESTROGEN THERAPY STEROID DOSE SHOULD BE REDUCED & INCREASED WHEN OESTROGEN IS TERMINATED
|
OESTROGENS CAUSE INCREASED LEVELS OF CORTICOSTEROID-BINDING GLOBULIN THEREBY INCREASING BOUND FRACTION, BUT ITS METABOLISM IS ALSO DECREASED.SO WITH OESTROGEN THERAPY STEROID DOSE SHOULD BE REDUCED & INCREASED WHEN OESTROGEN IS TERMINATED
|
OESTROGENS CAUSE INCREASED LEVELS OF CORTICOSTEROID-BINDING GLOBULIN THEREBY INCREASING BOUND FRACTION, BUT ITS METABOLISM IS ALSO DECREASED.SO WITH OESTROGEN THERAPY STEROID DOSE SHOULD BE REDUCED & INCREASED WHEN OESTROGEN IS TERMINATED
|
OESTROGENS CAUSE INCREASED LEVELS OF CORTICOSTEROID-BINDING GLOBULIN THEREBY INCREASING BOUND FRACTION, BUT ITS METABOLISM IS ALSO DECREASED.SO WITH OESTROGEN THERAPY STEROID DOSE SHOULD BE REDUCED & INCREASED WHEN OESTROGEN IS TERMINATED
|
CONCURRENT ADMINISTRATION MAY LEAD TO INCREASED G.I. SIDE EFFECTS
|
CORTICOSTEROIDS CAN DECREASE SERUM CONCENTRATION OF ANTIMUSCARINIC AGENTS
|
CORTICOSTEROIDS IF USED CONCOMITANTLY MAY LEAD TO PULMONARY EDEMA
|
CONCURRENT USE MAY CAUSE / POTENTIATE HYPOKALEMIA WHICH COULD PREDISPOSE THE PATIENT TO CARDIAC DYSFUNCTION
|
AMIODARONE SHOULD BE USED WITH CAUTION WITH DRUGS THAT INDUCE HYPOKALEMIA AND /OR HYPOMAGNESEMIA
|
CONCURRENT USE MAY CAUSE / POTENTIATE HYPOKALEMIA WHICH COULD PREDISPOSE THE PATIENT TO CARDIAC DYSFUNCTION
|
CO-ADMINISTRATION MAY INCREASE CHANCES OF HYPOKALEMIA
|
NSAIDS CONCURRENT ADMINISTRATION MAY INCREASE THE INCIDENCE OF G.I. SIDE EFFECTS
|
APROTININ IS INCOMPATIBLE WITH THE DRUG
|
CORTICOSTEROIDS MAY INCREASE EXCRETION OF THE DRUG
|
CONCURRENT ADMINISTRATION MAY LEAD TO INCREASED G.I. SIDE EFFECTS
|
CO-ADMINISTRATION MAY RESULT IN AN INCREASED OF G.I. ULCERATION OR OTHER COMPLICATIONS ; LOW DOSE OF ASPIRIN CAN BE USED WITH CELECOXIB
|
CONCURRENT USE MAY CAUSE / POTENTIATE HYPOKALEMIA WHICH COULD PREDISPOSE THE PATIENT TO CARDIAC DYSFUNCTION
|
CONCURRENT ADMINISTRATION MAY LEAD TO INCREASED G.I. SIDE EFFECTS
|
CORTICOSTEROIDS CAN AFFECT THE RESPONSE OF ITS THERAPY
|
CORTICOSTEROIDS MAY INCREASE EXCRETION OF THE DRUG
|
CONCURRENT ADMINISTRATION MAY LEAD TO INCREASED G.I. SIDE EFFECTS
|
NSAIDS CONCURRENT ADMINISTRATION MAY INCREASE THE INCIDENCE OF G.I. SIDE EFFECTS
|
NSAIDS CONCURRENT ADMINISTRATION MAY INCREASE THE INCIDENCE OF G.I. SIDE EFFECTS
|
CORTICOSTEROIDS MAY INTERFERE WITH THE DEVELOPMENT OF IMMUNE REACTION
|
HYPOKALEMIC EFFECT OF CORTICOSTEROIDS IS POTENTIATED
|
OESTROGENS INCREASE LEVEL OF CORTICOSTEROID-BINDING GLOBULIN THERE BY INCREASING BOUND FRACTION, BUT ITS METABOLISM IS ALSO DECREASED,SO STEROID DOSE SHOULD BE REDUCED BUT INCREASED DOSE MAY BE REQUIRED WHEN OESTROGEN IS TERMINATED
|
CONCURRENT ADMINISTRATION MAY LEAD TO INCREASED G.I. SIDE EFFECTS
|
CORTICOSTEROIDS, TEND TO PRODUCE HYPERGLYCEMIA AND MAY LEAD TO LOSS OF GLYCEMIC CONTROL
|
CORTICOSTEROIDS MAY INCREASE EXCRETION OF THE DRUG
|
CONCURRENT ADMINISTRATION MAY LEAD TO INCREASED G.I. SIDE EFFECTS
|
CORTICOSTEROIDS MAY INTERFERE WITH THE DEVELOPMENT OF IMMUNE REACTION
|
HYPOKALEMIC EFFECT OF CORTICOSTEROIDS IS POTENTIATED
|
CONCURRENT ADMINISTRATION MAY LEAD TO INCREASED G.I. SIDE EFFECTS
|
CORTICOSTEROIDS TEND TO PRODUCE HYPERGLYCEMIA LEADING TO LOSS OF DIABETES CONTROL
|
NSAIDS CONCURRENT ADMINISTRATION MAY INCREASE THE INCIDENCE OF G.I. SIDE EFFECTS
|
HYPOKALEMIC EFFECT OF CORTICOSTEROIDS IS POTENTIATED
|
CONCURRENT USE MAY CAUSE / POTENTIATE HYPOKALEMIA WHICH COULD PREDISPOSE THE PATIENT TO CARDIAC DYSFUNCTION
|
HYPOKALEMIC EFFECT OF CORTICOSTEROIDS IS POTENTIATED
|
OESTROGENS INCREASE LEVEL OF CORTICOSTEROID-BINDING GLOBULIN THERE BY INCREASING BOUND FRACTION, BUT ITS METABOLISM IS ALSO DECREASED,SO STEROID DOSE SHOULD BE REDUCED BUT INCREASED DOSE MAY BE REQUIRED WHEN OESTROGEN IS TERMINATED
|
OESTROGENS INCREASE LEVEL OF CORTICOSTEROID-BINDING GLOBULIN THERE BY INCREASING BOUND FRACTION, BUT ITS METABOLISM IS ALSO DECREASED,SO STEROID DOSE SHOULD BE REDUCED BUT INCREASED DOSE MAY BE REQUIRED WHEN OESTROGEN IS TERMINATED
|
OESTROGENS INCREASE LEVEL OF CORTICOSTEROID-BINDING GLOBULIN THERE BY INCREASING BOUND FRACTION, BUT ITS METABOLISM IS ALSO DECREASED,SO STEROID DOSE SHOULD BE REDUCED BUT INCREASED DOSE MAY BE REQUIRED WHEN OESTROGEN IS TERMINATED
|
CORTICOSTEROIDS TEND TO PRODUCE HYPERGLYCEMIA LEADING TO LOSS OF DIABETES CONTROL
|
CORTICOSTEROIDS TEND TO PRODUCE HYPERGLYCEMIA LEADING TO LOSS OF DIABETES CONTROL
|
CORTICOSTEROIDS TEND TO PRODUCE HYPERGLYCEMIA LEADING TO LOSS OF DIABETES CONTROL
|
CORTICOSTEROIDS TEND TO PRODUCE HYPERGLYCEMIA LEADING TO LOSS OF DIABETES CONTROL
|
CORTICOSTEROIDS TEND TO PRODUCE HYPERGLYCEMIA LEADING TO LOSS OF DIABETES CONTROL
|
HYPOKALEMIC EFFECT OF CORTICOSTEROIDS IS POTENTIATED
|
CONCURRENT USE MAY CAUSE / POTENTIATE HYPOKALEMIA WHICH COULD PREDISPOSE THE PATIENT TO CARDIAC DYSFUNCTION
|